Literature DB >> 19006379

Triazine compounds as antagonists at Bv8-prokineticin receptors.

Gianfranco Balboni1, Ilaria Lazzari, Claudio Trapella, Lucia Negri, Roberta Lattanzi, Elisa Giannini, Annalisa Nicotra, Pietro Melchiorri, Sergio Visentin, Chiara De Nuccio, Severo Salvadori.   

Abstract

On the basis of a Janssen's patent, we approached a new synthesis of some 1,3,5-triazin-4,6-diones as potential non peptidic prokineticin receptor antagonists, containing the following substitutions: (N(1) and N(5) link a 4-methoxybenzyl and a 4-ethylbenzyl, respectively; C(2) can link an amino-ethyl-guanidine (reference compound 1) or an ethylendiamine (2) or an amino-ethyl-amino-2-imidazoline (3). New compounds were assessed for PKR1 and PKR2 affinity. Antagonist properties were evaluated as inhibition of 1 nM Bv8-induced intracellular Ca2+ mobilization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19006379     DOI: 10.1021/jm800854e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain.

Authors:  Orit Jacobson; Ido D Weiss; Gang Niu; Gianfranco Balboni; Cenzo Congiu; Valentina Onnis; Dale O Kiesewetter; Roberta Lattanzi; Severo Salvadori; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

2.  Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives.

Authors:  Norikazu Sakakibara; Gianfranco Balboni; Cenzo Congiu; Valentina Onnis; Yosuke Demizu; Takashi Misawa; Masaaki Kurihara; Yoshihisa Kato; Tokumi Maruyama; Masaaki Toyama; Mika Okamoto; Masanori Baba
Journal:  Antivir Chem Chemother       Date:  2015-10-28

3.  Prokineticin 2 is an endangering mediator of cerebral ischemic injury.

Authors:  Michelle Y Cheng; Alex G Lee; Collin Culbertson; Guohua Sun; Rushi K Talati; Nathan C Manley; Xiaohan Li; Heng Zhao; David M Lyons; Qun-Yong Zhou; Gary K Steinberg; Robert M Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

4.  Pharmacological activity of a Bv8 analogue modified in position 24.

Authors:  R Lattanzi; P Sacerdote; S Franchi; M Canestrelli; R Miele; D Barra; S Visentin; C DeNuccio; F Porreca; M De Felice; F Guida; L Luongo; V de Novellis; S Maione; L Negri
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

5.  Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals.

Authors:  D Maftei; V Marconi; F Florenzano; L A Giancotti; M Castelli; S Moretti; E Borsani; L F Rodella; G Balboni; L Luongo; S Maione; P Sacerdote; L Negri; R Lattanzi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  Peripheral administration of prokineticin 2 potently reduces food intake and body weight in mice via the brainstem.

Authors:  Kel Beale; J V Gardiner; G A Bewick; K Hostomska; N A Patel; S S Hussain; C N Jayasena; F J P Ebling; P H Jethwa; H M Prosser; R Lattanzi; L Negri; M A Ghatei; S R Bloom; W S Dhillo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain.

Authors:  Elisa Giannini; Roberta Lattanzi; Annalisa Nicotra; Antonio F Campese; Paola Grazioli; Isabella Screpanti; Gianfranco Balboni; Severo Salvadori; Paola Sacerdote; Lucia Negri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

8.  An EG-VEGF-Dependent Decrease in Homeobox Gene NKX3.1 Contributes to Cytotrophoblast Dysfunction: A Possible Mechanism in Human Fetal Growth Restriction.

Authors:  Padma Murthi; Sophie Brouillet; Anita Pratt; Anthony Borg; Bill Kalionis; Frederic Goffin; Vassilis Tsatsaris; Carine Munaut; Jean-Jacques Feige; Mohamed Benharouga; Thierry Fournier; Nadia Alfaidy
Journal:  Mol Med       Date:  2015-07-21       Impact factor: 6.354

9.  Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs.

Authors:  Anat Levit; Talia Yarnitzky; Ayana Wiener; Rina Meidan; Masha Y Niv
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

10.  Critical role for prokineticin 2 in CNS autoimmunity.

Authors:  Mhamad Abou-Hamdan; Massimo Costanza; Elena Fontana; Marco Di Dario; Silvia Musio; Cenzo Congiu; Valentina Onnis; Roberta Lattanzi; Marta Radaelli; Vittorio Martinelli; Severo Salvadori; Lucia Negri; Pietro Luigi Poliani; Cinthia Farina; Gianfranco Balboni; Lawrence Steinman; Rosetta Pedotti
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.